A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy

Journal:

Kidney International

Published:

2026-01-01

DOI:

10.1016/j.kint.2025.11.017

Affiliations:

7

Authors:

11

Go to article

Institutions	Authors	Share
Ionis Pharmaceuticals, United States of America (USA)	6.000000	0.55
Sunnybrook Health Sciences Centre, U of T, Canada	1.000000	0.09
The University of British Columbia (UBC), Canada	1.000000	0.09
Genentech, Inc., United States of America (USA)	1.000000	0.09
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)	1.000000	0.09
New Zealand Clinical Research (NZCR), New Zealand	1.000000	0.09

Interested in Immunology?